Reaction of N-(R-cyclopropyl)benzimidoyl chloride with triethyl phosphite has yielded the corresponding N-(R-cyclopropyl)-substituted benzimidoyl phosphonates existing predominantly in the E-configuration [E : Z a parts per thousand (8-10) : 1] at room temperature. F-19 NMR spectroscopy allowed determination of inductive and resonance sigma-constants of N-(R-cyclopropyl)-substituted imidoyl chloride and imidoyl phosphonate groups for the first time.
Reaction of N-(R-cyclopropyl)benzimidoyl chloride with triethyl phosphite has yielded the corresponding N-(R-cyclopropyl)-substituted benzimidoyl phosphonates existing predominantly in the E-configuration [E : Z a parts per thousand (8-10) : 1] at room temperature. F-19 NMR spectroscopy allowed determination of inductive and resonance sigma-constants of N-(R-cyclopropyl)-substituted imidoyl chloride and imidoyl phosphonate groups for the first time.
Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof
申请人:REICH Melanie
公开号:US20090069320A1
公开(公告)日:2009-03-12
Substituted 4-amino-quinazoline compounds corresponding to formula I
methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.
[EN] ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS<br/>[FR] DÉRIVÉS D'ISOQUINOLINONE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS NK3
申请人:LUNDBECK & CO AS H
公开号:WO2010028655A1
公开(公告)日:2010-03-18
The invention relates to isoquinolinone derivatives useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
[EN] ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS<br/>[FR] DÉRIVÉS D'ISOQUINOLINONE COMME ANTAGONISTES DU NK3
申请人:LUNDBECK & CO AS H
公开号:WO2010045948A1
公开(公告)日:2010-04-29
Isoquinolone derivatives of the general formula (I) are NK3 antagonists.
通式(I)的异喹啉衍生物是NK3拮抗剂。
11 Beta-HSD1 Modulators
申请人:Martin Richard
公开号:US20090247515A1
公开(公告)日:2009-10-01
A compound according to Formula A:
or a pharmaceutically acceptable salt thereof, wherein
R
11
, G
1
and G
2
are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
A compound according to Formula I:
or a pharmaceutically acceptable salt thereof, wherein
R
1
, R
2
, R
11
, L
1
and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.